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ASSESSMENT OF SECOND AND THIRD GENERATION ORAL CONTRACTIVES APC RESISTANCE 
BY A NEWLY VALIDATED ETP-BASED APC RESISTANCE ASSAY. A PILOT STUDY.
BACKGROUND
v ETP-based APC resistance has been identified as a marker of the prothrombotic
state observed in women taking combined oral contraceptives (COCs) and figures
as a requirement for the investigation of steroid contraceptives.1
v In absence of any standardized procedure and validated methodology, which
impers a proper study-to-study comparison, the development of a test validated
against regulatory standards, is required.2
METHOD
v Resistance to APC was assessed on the Calibrated Automated Thrombogram (CAT)
with the Thrombinoscope software, using commercially available CE-marked
thrombin generation dedicated kit reagents from Diagnostica Stago.
v A total of 37 volunteers (FV Leiden negative) aged from 18-35 years were enrolled
and stratified into several subgroups:
§ Men (n=16)
§ Women not using hormonal contraception (no COC) [n=9]
§ Women using second-generation COC (2G COC) [n=7]
§ Women using third-generation COC (3G COC) [n=5]
v These subgroups have been compared based on their APC resistance values
expressed in inhibition percentage (%) of the ETP.
v Inhibition % of the ETP represents the comparison between the ETP measured in
presence and in absence of a defined amount of exogenous APC. This ratio (%),
subtracted to 100%, gives the inhibition % :
§ Inhibition % = 100% - !"#$%& '() (+,)-)!"#$%& '() (/,)-)
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RESULTS
The demographic characteristics (age and BMI) of the four groups were well matched 
(p-value > 0.05). 
A. Thrombin generation 
v In absence of APC
§ In women not using hormonal contraception, thrombin generation was
slightly higher (ETP ± SD = 1247 ± 236.6 nm.min) but not significant compared
to men (ETP ± SD = 1172 ± 151.8 nm.min).
§ In women taking COC (ETP ± SD = 1758 ± 316.3 nm.min), we observed
significant increase of thrombin generation compared to men (p-value
<0.0001) and women not using hormonal contraception (p-value <0.001).
[►Figure 1]
B. Inhibition %
v Mean inhibition % (± SD) of men and women not using hormonal contraception
were 92% (± 4%) and 75 % (± 10%) (p-value<0.0001)
v Mean inhibition % (± SD) of 2nd generation COC users and 3rd generation COC
users were 61% (± 20%) and 45 % (± 7%) respectively.
v Compared to men, differences were significant (p-value < 0.0001) and compared to
women not using COC, the difference was significant only in women using 3rd
generation COC (p-value = 0.001). [►Figure 3]
v A trend towards a significant difference between 2nd and 3rd COC generation was
observed but our pilot study was not sufficiently powered and was not designed for
this endpoint. [►Figure 3]
v We estimated at 24 the number of women (12 using 2nd generation COC and 12 using
3rd generation COC) needed likely to observe significant difference between
subgroups.
Figure 3 : Inhibition % of the ETP of men, women not
using hormonal contraception (no COC), women
using 2nd generation COC (2G COC) and women
using 3rd generation COC (3G COC).
*** p-value<0.001; **** p-value<0.0001
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AIM
To assess the sensitivity of a newly developed and validated ETP-based APC
resistance assay in plasmas from healthy volunteers and from women using COCs.
CONCLUSION
This newly validated APC resistance test is sensitive to differentiate men from
women not using hormonal contraception, and can also differentiate different
levels of APC resistance based on the type of COC.
The availability of a universal assay for evaluating ETP-based APC resistance is
welcome and will finally allow study-to-study comparison in order to assess the
APC resistance in different populations.
The implementation of this validated assay in routine can also identify subjects
with higher absolute risk at baseline, which may help the physician regarding his
prescription choices.
v In presence of APC
§ We observed a higher resistance to APC in women not using hormonal
contraception compared to men which was even more pronounced in
women taking 2nd and 3rd COC.
§ Graphically, the AUC below the red curves (+APC) in women taking COC
(2nd and 3rd generation) are higher compared to men and women not using
hormonal contraception. [►Figure 2]
Figure 1 : Mean ETP ± SD of men, women
not using hormonal contraception (no COC)
and women using COC (2nd and 3rd
generation mixed).
*** p-value<0.001; **** p-value<0.0001.
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Figure 2: Thrombin generation curves of men, women not
using hormonal contraception (w/o COC), women using 2nd
generation COC (2G COC) and women using 3rd generation
COC (3G COC). Blue curves represent thrombin generation in
absence of APC (-APC) and red curves in presence of exogenous
APC (+APC).
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